廖海荣;姚军;李曼;

• 1:桂林医学院附属医院生殖医学中心

摘要(Abstract)：

目前,卵巢低反应(POR)的治疗对生殖医师仍具有挑战性。当前定义POR的标准对患者的特征描述不足,且没有为临床医生提供治疗管理的指南。2016年Alvi99i等制定了一种新颖的标准,即波塞冬标准(Patient-Oriented Strategies Encompassing Individualize D Oocyte Number,POSEIDON),旨在提供更细致、合理的分类,并指导医生管理此类患者。然而,其标准设定的准确性、诊断价值以及分层管理的利益均有待进一步的临床研究和验证。

关键词(KeyWords)： 波塞冬标准;卵巢低预后;卵巢低反应;卵巢储备;ART计算器

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(No:81860285);; 桂林市科学研究与技术开发计划(No:20160226-1-3)

作者(Authors): 廖海荣;姚军;李曼;

DOI: 10.13283/j.cnki.xdfckjz.2020.11.013

参考文献(References)：

• [1] Ubaldi F,Vaiarelli A,D'Anna R,et al.Management of poor responders in IVF:is there anything new?[J]. Biomed Res Int,2014,2014:352098
• [2]乔杰，马彩虹，刘嘉茵，等.辅助生殖促排卵药物治疗专家共识[J].生殖与避孕，2015,35(04):211-223
• [3] Polyzos NP,Devroey P.A systematic review of randomized trials for the treatment of poor ovarian responders:is there any light at the end of the tunnel?[J].Fertil Steril,2011,96(5):1058-1061
• [4] Garcia JE,Jones GS,Acosta AA,et al.Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration:phase II,1981[J]. Fertil Steril,1983,39(2):174-179
• [5] Shanbhag S,Aucott L,Bhattacharya S,et al.Interventions for'poor responders'to controlled ovarian hyperstimulation(COH)in in-vitro fertilisation(IVF)[J].Cochrane Database Syst Rev,2007(1):D4379
• [6] Pandian Z,Mctavish AR,Aucott L,et al.Interventions for'poor responders'to controlled ovarian hyper stimulation(COH)in in-vitro fertilisation(IVF)[J].Cochrane Database Syst Rev,2010(1):D4379
• [7] Ferraretti AP,La Marca A,Fauser BC,et al.ESHRE consensus on the definition of'poor response'to ovarian stimulation for in vitro fertilization:the Bologna criteria[J].Hum Reprod,2011,26(7):1616-1624
• [8] Papathanasiou A.Implementing the ESHRE'poor responder'criteria in research studies:methodological implications[J].Hum Reprod,2014,29(9):1835-1838
• [9] Boza A,Oguz SY,Misirlioglu S,et al.Utilization of the Bologna criteria:a promise unfulfilled? A review of published and unpublished/ongoing trials[J].Fertil Steril,2018,109(1):104-109
• [10] Conforti A,Esteves SC,Picarelli S,et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology:the POSEIDON concept[J].Panminerva Med,2019,61(1):24-29
• [11] Bozdag G,Polat M,Yarali I,et al.Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria[J]. Reprod Biomed Online,2017,34(6):639-644
• [12] La Marca A,Grisendi V,Giulini S,et al.Live birth rates in the different combinations of the Bologna criteria poor ovarian responders:a validation study[J]. J Assist Reprod Genet,2015,32(6):931-937
• [13] Esteves SC,Roque M,Bedoschi GM,et al.Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology:POSEIDON Criteria-The Why[J].Front Endocrinol(Lausanne),2018,9:461
• [14] La Marca A,Sunkara SK.Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers:from theory to practice[J]. Hum Reprod Update,2014,20(1):124-140
• [15]黄宝怡，许培，刘曼婷，等.卵巢抵抗综合征分级及病因研究[J].中国实用妇科与产科杂志，2017,33(9):963-966
• [16] Alviggi C,Conforti A,Caprio F,et al.In estimated good prognosis patients could unexpected"hyporesponse"to controlled ovarian stimulation be related to genetic polymorphisms of FSH receptor?[J]. Reprod Sci,2016,23(8):1103-1108
• [17] Lehert P,Kolibianakis EM,Venetis CA,et al.Recombinant human follicle-stimulating hormone(r-hFSH)plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology:systematic review and meta-analysis[J]. Reprod Biol Endocrinol,2014,12:17
• [18] Alviggi C,Conforti A,Esteves S C,et al.Recombinant luteinizing hormone supplementation in assisted reproductive technology:a systematic review[J]. Fertil Steril,2018,109(4):644-664
• [19]谢幸，孔北华，段涛.妇产科学[M].第9版.北京:人民卫生出版社，2018:19
• [20]刘传明，丁利军，李佳音，等.衰老导致卵巢功能低下研究进展[J].遗传，2019,41(9):816-826
• [21] Li Q,Geng X,Zheng W,et al.Current understanding of ovarian aging[J]. Sci China Life Sci,2012,55(8):659-669
• [22] Gruhn JR,Zielinska AP,Shukla V,et al.Chromosome errors in human eggs shape natural fertility over reproductive life span[J].Science,2019,365(6460):1466-1469
• [23] Franasiak JM,Forman EJ,Hong KH,et al.The nature of aneuploidy with increasing age of the female partner:a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening[J].Fertil Steril,2014,101(3):656-663
• [24]陈雯，冯玲，Schmutzler A，等.女性年龄与卵细胞染色体非整倍体异常的相关关系[J].中国妇幼保健，2004,29(11):24-26
• [25] Wallace WH,Kelsey TW. Human ovarian reserve from conception to the menopause[J]. PLoS One,2010,5(1):e8772
• [26] Patrizio P,Vaiarelli A,Levi SP,et al.How to define,diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics[J].Reprod Biomed Online,2015,30(6):581-592
• [27] Alviggi C,Andersen CY,Buehler K,et al. A new more detailed stratification of low responders to ovarian stimulation:from a poor ovarian response to a low prognosis concept[J].Fertil Steril,2016,105(6):1452-1453
• [28] Grisendi V,Mastellari E,La Marca A. Ovarian reserve markers to identify poor responders in the context of poseidon classification[J]. Front Endocrinol(Lausanne),2019,10:281
• [29] Polyzos NP,Drakopoulos P. Management strategies for POSEIDON's Group 1[J]. Front Endocrinol(Lausanne),2019,10:679
• [30] Levi-Setti PE,Zerbetto I,Baggiani A,et al.An observational retrospective cohort trial on 4,828 IVF cycles evaluating different low prognosis patients following the POSEIDON Criteria[J]. Front Endocrinol(Lausanne),2019,10:282
• [31] Buhler KF.Commentary:Management Strategies for POSEIDON Groups 3 and 4[J]. Front Endocrinol(Lausanne),2019,10:920
• [32] Ata B,Kaplan B,Danzer H,et al. Array CGH analysis shows that aneuploidy is not related to the number of embryos generated[J]. Reprod Biomed Online,2012,24(6):614-620
• [33] Haahr T,Esteves SC,Humaidan P. Individualized controlled ovarian stimulation in expected poor-responders:an update[J].Reprod Biol Endocrinol,2018,16(1):20
• [34] Huang MC,Tzeng SL,Lee CI,et al.GnRH agonist long protocol versus GnRH antagonist protocol for various aged patients with diminished ovarian reserve:A retrospective study[J].PLoS One,2018,13(11):e207081
• [35] Chen SN,Tsui KH,Wang PH,et al. Dehydroepiandrosterone supplementation improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve[J].Front Endocrinol(Lausanne),2019,10:800
• [36] Esteves SC,Alviggi C,Humaidan P,et al. The POSEIDON criteria and its measure of success through the eyes of clinicians and embryologists[J]. Front Endocrinol(Lausanne),2019,10:814
• [37] Esteves SC,Carvalho JF,Bento FC,et al.A novel predictive model to estimate the number of mature oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization/intracytoplasmic sperm injection:the ART calculator[J].Front Endocrinol(Lausanne),2019,10:99